880 related articles for article (PubMed ID: 22503020)
1. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
Chen YC; Kuo HC
Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
[TBL] [Abstract][Full Text] [Related]
6. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
8. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
9. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis.
Kennelly M; Dmochowski R; Ethans K; Karsenty G; Schulte-Baukloh H; Jenkins B; Thompson C; Li D; Haag-Molkenteller C
Urology; 2013 Mar; 81(3):491-7. PubMed ID: 23290144
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
13. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity.
Apostolidis A; Thompson C; Yan X; Mourad S
World J Urol; 2013 Dec; 31(6):1469-74. PubMed ID: 23160758
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
16. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study.
Krhut J; Samal V; Nemec D; Zvara P
Spinal Cord; 2012 Dec; 50(12):904-7. PubMed ID: 22801191
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
Sengoku A; Okamura K; Kimoto Y; Ogawa T; Namima T; Yamanishi T; Yokoyama T; Akino H; Maeda Y
Int J Urol; 2015 Mar; 22(3):306-9. PubMed ID: 25403926
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo-controlled, double-blind trial with an open-label extension.
Honda M; Yokoyama O; Takahashi R; Matsuda T; Nakayama T; Mogi T
Int J Urol; 2021 Sep; 28(9):906-912. PubMed ID: 34075630
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
[TBL] [Abstract][Full Text] [Related]
20. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial.
Giannantoni A; Gubbiotti M; Rubilotta E; Balzarro M; Antonelli A; Bini V
Minerva Urol Nephrol; 2022 Oct; 74(5):625-635. PubMed ID: 33769020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]